Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.70 |
| ▸ | RAB9A | P51151 | 9/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.70 |
| ▸ | PKM | P14618 | 2/20 | 0.70 |
| ▸ | TP53 | P04637 | 4/20 | 0.67 |
| ▸ | HPGD | P15428 | 4/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | VDR | P11473 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.67 |
| ▸ | AHR | P35869 | 1/20 | 0.67 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.67 |
| ▸ | RELA | Q04206 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29528892 | 1.00 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL179157 | 0.88 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL19876187 | 0.88 | ALDH1A1 (0.65) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL16147181 | 0.88 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL3417301 | 0.84 | NPC1 (0.78) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL23758270 | 0.83 | AURKA (0.55) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL23736199 | 0.83 | TP53 (0.65) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL31679074 | 0.83 | TP53 (0.65) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL31154259 | 0.83 | NPC1 (0.68) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL2242715 | 0.83 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1684736-B1 | DNA DAMAGE REPAIR INHIBITORS FOR TREATMENT OF CANCER | KUDOS PHARM LTD (GB) | 2011-08-24 | — | — | EP | claimed |
| US-20250381221-A1 | Compositions and Methods for Treating Cancer | IN8BIO INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250161247-A1 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | LANTERN PHARMA INC. (US) | 2025-05-22 | — | — | US | disclosed |
| US-20240299322-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | LANTERN PHARMA INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240245643-A1 | DNA Damage Repair Inhibitors for Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-25 | — | — | US | disclosed |
| CN-116635028-A | Modulators of c-MYC mRNA translation and their use in the treatment of cancer | 艾尼莫生物科技公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20220339179-A1 | TREATMENT OF HR DEFICIENT CANCER | THE FRANCIS CRICK INSTITUTE LIMITED (GB) | 2022-10-27 | — | — | US | disclosed |
| EP-4028009-A1 | TREATMENT OF HR DEFICIENT CANCER | The Francis Crick Institute Limited (GB) | 2022-07-20 | — | — | EP | disclosed |
| US-20220047554-A1 | COMPOSITIONS AND METHODS FOR BLOCKING SODIUM CHANNELS | UNIVERSITY OF VIRGINIA | 2022-02-17 | — | — | US | disclosed |
| US-11162095-B2 | Use of a combination of Dbait molecule and PARP inhibitors to treat cancer | INSTITUT CURIE (FR) | 2021-11-02 | — | — | US | disclosed |
| EP-2167086-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | AstraZeneca AB (SE) | 2010-03-31 | — | — | EP | disclosed |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT (OXFORD) LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| WO-2008146035-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | WO | disclosed |
| EP-1986633-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008020180-A2 | METHODS OF INCREASING THE SENSITIVITY OF CANCER CELLS TO DNA DAMAGE | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007091106-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
| EP-1684736-A1 | DNA DAMAGE REPAIR INHIBITORS FOR TREATMENT OF CANCER | Kudos Pharmaceuticals Limited (GB) | 2006-08-02 | — | — | EP | disclosed |
| US-20060142231-A1 | DNA damage repair inhibitors for treatment of cancer | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-06-29 | — | — | US | disclosed |
| US-20050227919-A1 | DNA damage repair inhibitors for the treatment of cancer | KUDOS PHARMACEUTICALS LIMITED | 2005-10-13 | — | — | US | disclosed |
| WO-2005053662-A1 | DNA DAMAGE REPAIR INHIBITORS FOR TREATMENT OF CANCER | KUDOS PHARMACEUTICALS LIMITED (GB) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161247-A1 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | PARP1, PARP2, PARP3 | NPC1 4253/4885RAB9A 3131/4885SMN1; SMN2 3235/4885 |
| US-11162095-B2 | Use of a combination of Dbait molecule and PARP inhibitors to treat cancer | PARP10, PARP1, PARP3 | NPC1 3786/4885RAB9A 3874/4885SMN1; SMN2 4380/4885 |
| US-20240299322-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | PARP1, PARP2, PARP11 | NPC1 3852/4885RAB9A 2558/4885SMN1; SMN2 2427/4885 |
| US-20240245643-A1 | DNA Damage Repair Inhibitors for Treatment of Cancer | PARP2, MRE11, PARP1 | NPC1 4490/4885RAB9A 2456/4885SMN1; SMN2 3971/4885 |
| US-20060142231-A1 | DNA damage repair inhibitors for treatment of cancer | MRE11, PARP2, ERCC4 | NPC1 4486/4885RAB9A 2751/4885SMN1; SMN2 4031/4885 |
| US-20220047554-A1 | COMPOSITIONS AND METHODS FOR BLOCKING SODIUM CHANNELS | SCN3A, SCN1B, SCN2B | NPC1 483/4885RAB9A 2068/4885SMN1; SMN2 228/4885 |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | NPC1 3637/4885RAB9A 4325/4885SMN1; SMN2 9/4885 |
| US-20050227919-A1 | DNA damage repair inhibitors for the treatment of cancer | MRE11, ERCC4, PARP2 | NPC1 4509/4885RAB9A 2633/4885SMN1; SMN2 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.